Thymalin vs Thymosin Alpha-1

Thymalin: Original Khavinson thymic peptide complex — multi-peptide immunomodulator with 40-year Russian clinical track record. Typical dose 5,000-30,000 mcg. Thymosin Alpha-1: Thymic peptide with broad immunomodulatory activity, approved in over 35 countries. Typical dose 1000-1600 mcg. Both fall under the Bioregulators and Immune categories.

Stacking Thymalin with Thymosin Alpha-1 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Thymalin is typically dosed: Once daily IM or SubQ for Immune support (Russian clinical). Thymosin Alpha-1 is typically dosed: Twice weekly (SubQ) for Immune modulation; Twice weekly for Hepatitis treatment (clinical protocol); Daily for initial phase, then twice weekly for Acute immune support.

Thymalin: Not FDA approved. Thymosin Alpha-1: Not FDA approved. Granted orphan drug designation for hepatocellular carcinoma and hepatitis B. Multiple clinical trials conducted but no NDA submitted.